Simon Collins

Categories Covered:Managing Long-Term HIV Survivors, HIV Treatments in Development, PrEP (HIV Pre-Exposure Prophylaxis), HIV Prevention Methods, HIV Care and Services Outside the US, Adverse Events, Comorbidities, and HIV, Providing Quality HIV Care, Dolutegravir (Tivicay), HIV Epidemiology, First-Line HIV Treatment, Managing Primary/Acute HIV Infection, Managing People Newly Diagnosed With HIV, HIV Care Continuum, HIV Education and Risk Management, HIV Testing, FDA-Approved HIV Medications, Zerit (Stavudine, d4T), HIV in Specific Countries, Ritonavir (Norvir), Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF), HIV Policy and Advocacy, Abacavir (Ziagen), Tenofovir Disoproxil Fumarate (Viread), Pregnancy, Childbirth, and HIV, HIV in Film, TV, and Media, Managing HIV Drug Resistance, HIV Advocates in the Spotlight, Switching or Stopping HIV Treatment, HIV Treatment Strategies, Atazanavir (Reyataz), Raltegravir (Isentress), Darunavir (Prezista), Rilpivirine (Edurant), Cobicistat/Darunavir (Prezcobix), Pediatric HIV Care, Enfuvirtide (T-20, Fuzeon), Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla), Efavirenz (Sustiva, Stocrin), U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), Elvitegravir (Vitekta), Meeting the Costs of HIV Care, HIV, Discrimination, and Law, HIV in Books and Publishing, Didanosine (ddI, Videx), Maraviroc (Selzentry, Celsentri), Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate (Symfi Lo), PrEP (HIV Pre-Exposure Prophylaxis), HIV Prevention and Transmission, HIV Advocacy and Activism, Financial Issues, Etravirine (Intelence), PEP (HIV Post-Exposure Prophylaxis), Starting HIV Treatment and Medical Care, HIV and Mental Health Care, Stavudine (d4T, Zerit), Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild), Cobicistat (Tybost), Atazanavir/Cobicistat (Evotaz)

Latest by Simon Collins

New Option for PrEP: TAF/FTC Is Non-Inferior to TDF/FTC -- Results of Phase 3 DISCOVER Study

The results from this large study are notable, showing that a new version of PrEP is at least as affective at protecting against HIV infection as the currently approved formulation.

By Simon Collins for HIV i-Base

Viral Reservoir Can Explain Persistent Low Level Viremia With Good Adherence on ART

A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.

By Simon Collins for HIV i-Base

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base

UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants

The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.

By Simon Collins for HIV i-Base

NHS England Doubles Places on IMPACT PrEP Study to 26,000

Although the move means that more Britons might be able to access free PrEP, this study is also controversial for being seen as a way to delay full government approval.

By Simon Collins for HIV i-Base

FDA Approves Generic TDF/3TC for Use in the U.S.

The U.S. FDA has approved Temixys, a generic combination tablet of tenofovir disoproxil fumarate plus lamivudine.

By Simon Collins for HIV i-Base

Why U=U Does Not Cover Breastfeeding

"Undetectable equal untransmittable" is sometimes wrongly interpreted as covering all ways that HIV can be transmitted.

By Simon Collins for HIV i-Base

3D Imaging Videos Show HIV Infection Might Establish Within Hours

A fascinating lecture at this year's HIVR4P conference showed how advances in modern scanning technologies can be used to get more accurate information about the first stages of HIV infection and on the ways that HIV drugs are absorbed and distribute...

By Simon Collins for AVAC: Global Advocacy for HIV Prevention

How to Evaluate PrEP and Vaccines: Urgency for Next-Generation Compounds

Several presentations at the 2018 HIV Research for Prevention conference looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.

By Simon Collins for HIV i-Base

HIV Diagnoses in UK Drop for Third Year: Among All Ages, Risk Groups, and Ethnicities and Across Most UK Regions

Preliminary data released by Public Health England show that HIV diagnoses dropped by 17% in 2017 compared to 2016.

By Simon Collins for HIV i-Base